{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-08T20:31:17.137Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-08. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-08. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-08, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"VEEV\",\n  \"company\": \"Veeva Systems Inc.\",\n  \"investigation_summary\": \"Veeva Systems reported a Q1 FY27 beat (EPS $2.24 vs $2.14 est; revenue $882.9M vs $857.8M est) and raised full-year guidance on June 3, 2026. The stock is down ~46% from its 52-week high of $310.50 and now trades at a forward P/E of just 16.75x — a historically cheap multiple for a company growing revenue at 16-17%, posting consistent EPS beats (last 4 quarters averaging +5%), and launching an AI platform (Falcon) with enterprise commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery. The stock drop appears macro-driven (rotation away from high-multiple software), not fundamental: Q1 was clean, the balance sheet is pristine ($7.3B equity, ~$0 debt), gross margins are 75%, and Ostro acquisition closed in March 2026 adding AI-native patient engagement capability. No insider open-market purchases were detected — just director RSU vesting exercises. The combination of depressed valuation + confirmed upward guidance revision + near-term technical reprieve (MACD bullish cross, sitting at MA50) makes VEEV a strong income/range-bound candidate for covered calls or a structured put-write on further weakness.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Veeva Systems is the dominant cloud-software provider for the global life sciences industry, serving 1,552 customers including virtually every major pharmaceutical company (Eli Lilly, Gilead, Merck, Novartis, Bayer, Boehringer Ingelheim). Its platform spans four product categories: Commercial Cloud (CRM, marketing analytics), R&D and Quality Cloud (clinical data management, regulatory submission, quality management), Data Cloud (patient/HCP reference data, longitudinal prescriber data), all built on the proprietary Veeva Vault platform. Subscription revenue is ~83% of total ($730M of $883M in Q1). The company operates a land-and-expand model: initial footprint in one function then broadening across R&D and commercial workflows. FY2026 total revenues were $3.2B (+16% YoY), with FY27 Q1 at $882.9M (+16.3%). It completed the Ostro acquisition (March 2026) for ~$90M, adding an AI-driven patient/doctor engagement chatbot to its commercial stack. The Falcon agentic AI platform was announced in June 2026 as a layer across Vault applications — using Anthropic Claude models via AWS Bedrock — targeting clinical, regulatory, safety, and quality workflows.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-09-02\",\n      \"recent_eps_surprise_pattern\": \"4 consecutive quarters of positive EPS surprise: +4.75% (Q3 FY26), +4.55% (Q4 FY26), +6.45% (Q1 FY27 actual), +5.10% (most recent Q2). Guidance raised at most recent print.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q1 FY27 beat: EPS $2.24 vs $2.14 est (+4.9%); revenue $882.9M vs $857.8M est (+2.9%). Full-year guidance raised.\",\n          \"date_or_window\": \"2026-06-03\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/veev-20260603.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Veeva Falcon AI platform launch — agentic AI for clinical, regulatory, safety, and quality workflows on the Vault platform. New enterprise commitments from Merck KGaA, Teva Pharmaceuticals, Kindeva Drug Delivery.\",\n          \"date_or_window\": \"2026-06 announcement window\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/markets/stocks/articles/veeva-falcon-ai-rollout-tests-010535936.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"m&a\",\n          \"description\": \"Ostro acquisition closed March 9, 2026 for ~$90M — AI-driven patient engagement chatbot for life sciences.\",\n          \"date_or_window\": \"2026-03-09\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 16.75,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 20.3,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 4.59,\n      \"narrative\": \"VEEV trades at a forward P/E of ~16.75x — its lowest multiple in years and well below the 25-35x range it occupied during 2023-2025. The compression appears driven by macro rotation away from high-multiple SaaS rather than fundamental deterioration: revenue growth has held steady at 15-17%, gross margins are a best-in-class 75%, and the company just raised guidance. FCF yield of ~4.6% is attractive relative to risk-free alternatives.\"\n    },\n    \"quality\": {\n      \"roic_pct\": 13.9,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": false,\n      \"rsi_14\": 48.6,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 168.09,\n    \"ytd_return_pct\": -40.67,\n    \"from_52w_high_pct\": -45.86\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-20\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\",\n      \"key_takeaways\": [\n        \"FY2026 (ended Jan 2026): revenues $3.195B (+16% YoY), subscription $2.684B (+17%), non-GAAP operating income $1.49B; top 10 customers = 28% of revenue; 7,928 employees globally; no debt; net cash position ~$5-6B\",\n        \"CRM migration risk explicitly called out: legacy Veeva CRM (built on Salesforce infrastructure) supported through Dec 31, 2029; Vault CRM is the next-gen replacement built on proprietary Vault platform — customers have the option to move to Salesforce as their CRM provider instead\",\n        \"Non-practicing entity IP litigation risk flagged; competitive intensity in CRM market acknowledged\"\n      ]\n    },\n    {\n      \"form\": \"10-Q (Q1 FY27)\",\n      \"filed\": \"2026-06-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm\",\n      \"key_takeaways\": [\n        \"Q1 FY27: revenue $882.9M (+16% YoY), subscription $730.2M, professional services $152.8M; gross margin 75%; adjusted operating income $395.4M (45%); net income $260.9M; Ostro acquisition closed March 9 for ~$90M ($70M net of cash) adding $25.5M in intangibles and $44.4M in goodwill\",\n        \"Balance sheet: total assets $9.13B; cash + short-term investments $7.31B; total debt only $103M (lease liabilities); stockholders' equity $7.30B; share repurchase program authorized up to $2B, with $1.6B remaining as of Q1 close\",\n        \"FY27 revenue guidance: ~$3.68-3.70B (+15% at midpoint); Q2 FY27 revenue guidance: $903.5M midpoint (+17%); EPS non-GAAP ~$9.05-9.10\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-09-18\"\n    ],\n    \"iv_summary\": \"ATM IV on near-term (Jul) expiry: ~55-60%. At-the-money Sep 2026 (101 DTE) has mid-IV ~56% — elevated relative to VEEV's historical norm of 35-45%, reflecting uncertainty around the AI product rollout and CRM migration competition\",\n    \"notable_skew_or_flow\": \"Call-side net dollar bias (+$242K on Jul); OTM call whale block at $150 strike ($283K notional, 57.5% IV). Notable put positioning V/OI > 1 at $165 strike (108 vol / 86 OI = 1.26x new positioning) — downside protection being layered by institutions ahead of Q2 earnings in September.\"\n  },\n  \"competitive_landscape\": \"VEEV is the dominant pure-play life sciences cloud software provider, competing primarily with Salesforce (life-sciences-specific CRM module), IQVIA (data + commercial analytics, CRM licensing from Salesforce as of recently), and general enterprise vendors (Oracle, Microsoft) for replacement cycles. In R&D/Quality Cloud there are fewer direct competitors — IQVIA, Dassault Systèmes Biovia, OpenText, Honeywell for certain modules. The key competitive tension is the Vault CRM migration: some customers have committed to moving to Salesforce instead of upgrading to Vault CRM, and Salesforce has made explicit competitive inroads (IQVIA now licenses its CRM to Salesforce). This represents a real but bounded competitive risk — not existential given VEEV's deep R&D/Quality moat and 1,552-customer base.\",\n  \"key_risks\": [\n    \"CRM migration churn: some large customers have committed to moving to Salesforce instead of Vault CRM; ongoing competitive pressure on commercial side\",\n    \"Valuation is depressed due to macro rotation into value/defensive names — if rates stay elevated, re-rating may not come quickly\",\n    \"No insider buying in 90 days; no obvious near-term catalyst beyond Q2 earnings Sep 2026\",\n    \"Falcon AI platform has been announced but monetization timeline and customer adoption rate remain uncertain\",\n    \"Top-10 customers = ~28% revenue concentration\"\n  ],\n  \"what_the_market_might_be_missing\": \"The stock's -46% decline from its 52-week high is almost entirely multiple compression (from ~30x to ~17x forward P/E) rather than fundamental deterioration — the business continued delivering 16%+ revenue growth, consistent beats, and margin expansion throughout the selloff. The elevated IV environment (~56%) creates a structured income opportunity: a CSP or covered strangle at 90-95% of spot captures meaningful premium while being well-supported by VEEV's fortress balance sheet ($7.3B equity, ~$0 debt, $7.3B in cash+investments). The analyst consensus target of $248 implies ~48% upside — if the stock simply re-rates back to its 5-year average forward multiple of ~25x on the same earnings power, there is substantial recovery potential that options markets are not adequately pricing given elevated IV.\",\n  \"anti_signals_present\": [],\n  \"sources\": [\n    {\n      \"label\": \"Q1 FY27 10-Q\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm\"\n    },\n    {\n      \"label\": \"FY2026 10-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\"\n    },\n    {\n      \"label\": \"June 3, 2026 Earnings 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/veev-20260603.htm\"\n    },\n    {\n      \"label\": \"Earnings calendar + estimates\",\n      \"url\": \"earnings(VEEV)\"\n    },\n    {\n      \"label\": \"Falcon AI launch article\",\n      \"url\": \"https://finance.yahoo.com/markets/stocks/articles/veeva-falcon-ai-rollout-tests-010535936.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-08T20:32:24.652Z",
      "raw_content": "<think>The dossier is for VEEV (Veeva Systems Inc.).\nScout verdict: `range_bound_or_income`\nStructure hints: `cc`, `strangle`, `csp`\nMarket cap: Not explicitly given, but forward P/E 16.75, revenue ~$3.7B implies market cap around $6.2B. So `core` risk class.\nPrice context: last_close $168.09. Down ~46% from 52w high.\nIV: ATM IV ~55-60% (elevated).\nCatalyst: Q1 FY27 beat, raised guidance June 3, 2026. Next earnings Sep 2, 2026. Falcon AI platform launch June 2026.\nMispricing: Forward P/E 16.75 (historically cheap). FCF yield 4.59%.\nQuality: ROIC 13.9%, Gross margin 75%, Net cash $7.3B.\nTechnical: Above 50DMA, below 200DMA. RSI 48.6. MACD bullish cross.\nAnti-signals: None.\nSmart money: None detected.\nOptions flow: Call-side net dollar bias. OTM call whale block $150. Put positioning at $165.\nScoring:\nA. Smart Money: 0 (no insider buys, no 13F) -> 0\nB. Options Flow / UOA: 4 (call-side net dollar bias, OTM call whale block) -> ~4\nC. Catalyst: 10 (earnings within 90 days? Sep 2 is ~86 days away. Last 4 quarters EPS surprise > 0%: yes, +4.75, +4.55, +6.45, +5.10) -> 10. Plus guidance raise: +5. Cap at 25.\nD. Mispricing: 5 (forward P/E is 16.75, sector median not given but narrative says well below 25-35x range. Let's give 4 for EV/EBITDA or forward PE. Actually, narrative says \"well below sector median\" implicitly? I'll give 5 for forward PE gap).\nE. Quality: 5 (ROIC 13.9% close to 15, but gross margin 75% is expanding/stable. Net debt/EBITDA is ~0. Net cash. Let's give 5 for balance sheet/quality).\nF. Momentum/Technical: 3 (above 50DMA, RSI 40-65, MACD bullish cross) -> 3.\nTotal Score: ~27? Wait, that's low. Let's re-evaluate carefully against rubric.\nA: 0\nB: 4 (call blocks, bias)\nC: 15 (earnings + surprise pattern + guidance raise)\nD: 5 (forward PE significantly below historical/sector)\nE: 5 (balance sheet, ROIC decent)\nF: 3\nTotal: 32.\nThis is below 45. So skip is expected.\nWait, let's check thresholds.\nCore: <45 Skip.\nBut the dossier says \"strong income/range-bound candidate\".\nLet's score it strictly.\nA: 0\nB: 4\nC: 15\nD: 5\nE: 5\nF: 3\nSum: 32.\nReason to skip: Score < 45. Lack of smart money, technicals mixed (below 200DMA), valuation compression is macro-driven not necessarily a quick re-rating catalyst, elevated IV makes it an income play but Scout's verdict is range-bound/income and the prompt says \"If Scout supplied structure_hints[], they're a starting point. You can override...\". But the score is too low for a publication. I will skip.\nWait, could I push it to a paper track? Score 45-59. It's 32. So skip.\nLet's double check the scoring rubric.\nA: 0\nB: 4 (whale_call_blocks_otm ≥ 2? Dossier says \"OTM call whale block at $150 strike ($283K notional)\". Only 1 block mentioned. So maybe 0 or 1. I'll give 1.)\nC: 10 (earnings within 90 days + EPS surprise > 0% for 4 quarters) + 5 (guidance raise) = 15.\nD: 5 (forward P/E 16.75 vs sector median ~25-35x -> ≥20% below).\nE: 5 (ROIC 13.9% close to 15, net cash).\nF: 3 (above 50DMA, RSI 40-65, MACD cross).\nTotal: ~28.\nClearly skip.\nReason: Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and a valuation compression driven by macro rotation rather than a specific re-rating catalyst. The elevated IV environment supports an income structure, but without a clear directional edge or catalyst timing, it does not meet the bar for publication.\nI will output the skip JSON.\nCheck format: exactly the skip schema.\nAll good.\nLet's construct carefully.\nScore: 28\nBreakdown: smart_money: 0, options_flow: 1, catalyst: 15, mispricing: 5, quality: 5, technical: 3.\nReason: \"Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.\"\nMatches requirements. Output matches schema.\nDone. \nWait, let's verify D rubric: \"5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating earnings)\". Dossier says sector median is null, but narrative says \"well below the 25-35x range it occupied during 2023-2025\". I'll give it 4 pts to be safe, or 5. It doesn't change the <45 outcome.\nI will stick with 28.\nOutput matches exactly.\nProceed. \nOne minor check: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate\". It's empty here.\n\"EDGE CHECK: What does this idea say that the market doesn't already know?\" -> Market knows it's cheap, but macro rotation is the driver. No specific edge. Skip is correct.\nReady. \nOutput matches requested JSON structure.\n```json\n{\n  \"skip\": true,\n  \"score\": 28,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 1,\n    \"catalyst\": 15,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.\"\n}\n```\nAll constraints met. No extra text. Valid JSON. Dates checked (not applicable for skip). Risk class core (implied). Structure guidance ignored because skipping. Score < 45. Correct.\nProceeds. \nSelf-Correction/Refinement during thought: \nCould I justify a higher score? \nA: 0\nB: 4 (call-side net dollar bias >30%? Dossier says \"+$242K on Jul\". Not >30% of total. I'll stick with 1 or 2. Let's say 2 for net_dollar_bias if interpreted loosely, but 1 is safer.)\nC: 15\nD: 5\nE: 5\nF: 3\nTotal: ~30. Still <45. Skip is robust.\nI will output the skip JSON exactly. \nFinal check of the prompt: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will ensure strictly JSON output.\nDone. \nProceeds. \n[Output Generation] -> matches the refined JSON. \nNote: I will make sure the JSON is perfectly formatted. No markdown code blocks as requested.\nActually, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will strictly follow that.\nDone. \nOutput matches response. \nProceeds. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: { \"skip\": true, ... }\"\nAll good. \nOutput Generation. \n(Self-Correction/Verification during generation prep)\nWait, the prompt says \"market_cap field\" for risk class. The dossier doesn't explicitly state market cap, but implies ~$6B. I'll assume core. Doesn't change skip decision.\nScore breakdown sums to 28.\nReason is concise.\nReady. \nOutput matches. \n[Proceeds]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 28,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 1,\n    \"catalyst\": 15,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 28,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 1,\n    \"catalyst\": 15,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 28,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 1,\n    \"catalyst\": 15,\n    \"mispricing\": 5,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 67515,
  "stop_reason": "stop",
  "completed_at": "2026-06-08T20:32:24.652Z"
}